Natural product Miliusol derivative as well as preparation and application thereof in antitumor drugs
By optimizing the structure of Miliusol, compound 24 with significant anti-tumor activity was developed to treat triple-negative breast cancer, which solved the shortcomings of TNBC cell therapy in the prior art, and achieved effective inhibition of TNBC cells and tumors in vivo significantly reduced.
Patent Information
- Application Number
- CN202411252086.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-22
AI Technical Summary
Effective anti-tumor drugs are lacking in the prior art, especially treatment options for triple-negative breast cancer (TNBC) cells, and the pharmacological effects of Miliusol derivatives have not been fully developed.
By optimizing the structure of Miliusol, a series of Miliusol derivative compounds were developed and compounds with significant anti-tumor activity were prepared, including compound 24, which were used in various dosage forms such as tablets, capsules, solutions, etc. for single or Combined treatment of tumors.
Compound 24 significantly inhibited the proliferation and migration of TNBC cells, had high selectivity, showed more than 60 times selectivity to tumor cells, and significantly reduced tumor volume and weight in in vivo experiments, demonstrating good anti-TNBC potential. .
Smart Images

Figure CN118994075A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a natural product Miliusol derivative and its preparation and application in anti-tumor drugs, belonging to the technical field of anti-tumor drugs. Background Art
[0002] Yunnan wild angelica is a plant of the genus Miliusa of the Annonaceae family, which is mainly distributed in Menghai and Mengla areas of Yunnan Province. It is commonly used by the people to dispel cold and relieve pain, and dispel wind and dampness. The chemical composition and pharmacological effects of the plant have not been reported. Miliusol belongs to the homogentisic acid compound and was first isolated from Miliusa balansae in 2004. At the cellular level, Miliusol shows a broad spectrum of anti-tumor activity. The present invention is based on the structure of Miliusol, optimizes its structure, and obtains a series of structural derivatives, which have obvious anti-tumor activity and show high selectivity.
[0003] Summary of the invention
[0004] The technical problem solved by the present invention is to provide a preparation method of a Miliusol derivative having significant anti-tumor activity and the application of the derivative in the preparation of anti-tumor drugs.
[0005] The present invention provides a compound having a structural formula as shown in Formula I or a pharmaceutically acceptable salt thereof:
[0006]
[0007] in,
[0008] R is -CO(CH2) n NHCOOR1, -CO(CH2) m R2, -CO(CH2) p CONHR3, -CO(CH2) n NHCOR4;
[0009] R1 is C1-C6 alkyl, C1-C6 alkoxy;
[0010] R2 is C2-C8 alkenyl, substituted or unsubstituted 5-10 membered aryl or heteroaryl, the heteroaryl contains 1-3 heteroatoms of N, O or S, and the substituent is halogen, C1-C6 alkyl, C1-C6 alkoxy, -NHCOR5, -NHCOOR6;
[0011] R5 is C1-C6 alkyl, C1-C6 alkoxy, C2-C8 alkenyl, C3-C6 cycloalkyl, substituted or unsubstituted 5-6 membered aryl or heteroaryl, the heteroaryl contains 1-3 heteroatoms of N, O or S, and the substituent is halogen, C1-C6 alkyl, C1-C6 alkoxy;
[0012] R6 is C1-C6 alkyl, C1-C6 alkoxy;
[0013] R3 is (CH2) q R8;
[0014] R8 is
[0015] R4 is a substituted or unsubstituted C2-C8 alkenyl group, wherein the substituent is a 5-10 membered aryl or heteroaryl group, wherein the heteroaryl group contains 1-3 heteroatoms of N, O or S;
[0016] n is 0-4;
[0017] m is 0-4;
[0018] p is 0-4;
[0019] q is 0-4.
[0020] The present invention preferably comprises a compound having the following structure or a pharmaceutically acceptable salt thereof:
[0021] R1 is C1-C4 alkyl, C1-C4 alkoxy;
[0022] R2 is C2-C8 alkenyl, substituted or unsubstituted Phenyl, wherein the substituent is F, Cl, Br, C1-C4 alkyl, C1-C4 alkoxy, -NHCOR5, -NHCOOR6;
[0023] R5 is C1-C4 alkyl, C1-C4 alkoxy, C2-C4 alkenyl, C3-C6 cycloalkyl, substituted or unsubstituted Phenyl, halogen-substituted C1-C4 alkylphenyl, the substituent is C1-C4 alkyl, C1-C4 alkoxy;
[0024] R6 is C1-C6 alkyl, C1-C6 alkoxy;
[0025] R3 is (CH2) q R8;
[0026] R8 is R4 is a substituted or unsubstituted C2-C8 alkenyl group, wherein the substituent is n is 1-2;
[0027] m is 0-2;
[0028] p is 1-2;
[0029] q is 1-2.
[0030] The present invention preferably comprises a compound having the following structure or a pharmaceutically acceptable salt thereof:
[0031]
[0032] The pharmaceutically acceptable salt of the compound described in the present invention may be nitrate, hydrochloride, sulfate, phosphate or citrate of the compound.
[0033] The present invention also provides a pharmaceutical composition, which is a preparation containing an effective dose of the above-mentioned compound or a pharmaceutically acceptable salt thereof. The compounds of the present invention can be prepared in the following forms by methods known in the art: tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely dispersed powders or aerosols or sprays for inhalation, sterile aqueous or oily solutions or suspensions or sterile emulsions for extra-intestinal (including intravenous, intramuscular or infusion). Sterile water or water-propylene glycol solutions can be used as solvents to prepare liquid preparations, and the active ingredients can also be formulated in aqueous polyethylene glycol solutions. Aqueous solutions for oral administration can be prepared by dissolving the active ingredients in water and adding suitable colorants, flavoring agents, stabilizers and thickeners as needed. Aqueous suspensions for oral use can be prepared by dispersing the finely dispersed active ingredients in water together with a viscous substance, such as natural synthetic gums, resins, methylcellulose, carboxymethylcellulose and other suspending agents known in the pharmaceutical field.
[0034] The pharmaceutical composition may be in unit dosage form. In these forms, the composition is divided into unit doses containing appropriate quantities of the active ingredient. The unit dosage form may be a packaged preparation containing discrete quantities of the preparation, such as boxed tablets, capsules, and powders in vials or ampoules. The unit dosage form may also be a capsule, cachet, or tablet or it may be an appropriate number of any of these packaged forms.
[0035] The active ingredient of the pharmaceutical composition of the present invention may be the compound of the present invention alone, or may be combined with other anti-tumor compounds as the active ingredient.
[0036] The present invention provides the use of the above compound or its pharmaceutically acceptable salt or its pharmaceutical composition in the preparation of anti-tumor drugs.
[0037] Furthermore, the tumor is breast cancer, and the breast cancer is triple-negative breast cancer.
[0038] In the process of treating tumors, the compound of the present invention or its pharmaceutically acceptable salt can be used alone for treatment, or the pharmaceutical composition thereof can be used for combined treatment.
[0039] In treating tumors, such combined therapy can be achieved by administering the various therapeutic components simultaneously, sequentially or separately. Such combination products employ the compounds of the present invention within an effective dosage range and the other pharmaceutically active agents within an approved dosage range. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 ZMF-24 inhibits the proliferation of BT-549 cells and MDA-MB-231 cells.
[0041] AB: Representative images of ZMF-24 inhibiting the colony formation of BT-549 cells and MDA-MB-231 cells.
[0042] CD: Image J software was used to analyze the ability of ZMF-24 to inhibit TNBC cell cloning.
[0043] * p<0.05; *** p<0.001; **** p<0.0001.
[0044] EF: 3D tumor sphere formation assay detected that ZMF-24 (1 μM) inhibited the 3D tumor sphere formation of TNBC cells.
[0045] Scale bar = 1000 μm. Images were analyzed using Image J software to calculate the diameter of tumor spheres. **** p<0.0001.
[0046] G, I: EdU staining was used to analyze the effect of different concentrations of ZMF-24 on the proliferation of BT-549 and MDA-MB-231 cells. Image j was used to quantify the relative fluorescence intensity.
[0047] Scale bar = 200 μm. **** p<0.0001.
[0048] H, J Immunofluorescence assay to detect the relative expression of Ki-67 in BT-549 cells and MDA-MB-231 cells after treatment with different concentrations of ZMF-24. Scale bar = 100 μm. ** p<0.01; **** p<0.0001.
[0049] Figure 2 ZMF-24 inhibits the migration of BT-549 cells and MDA-MB-231 cells.
[0050] AB: Scratch assay was used to detect the effect of different concentrations of ZMF-24 on the migration of BT-549 cells and MDA-MB-231 cells.
[0051] Scale bar = 500 μm. ns, no significant difference; * p<0.05; ** p<0.01; *** p<0.001.
[0052] CD: Transwell assay to detect the effect of ZMF-24 (1 μM) on the migration ability of BT-549 cells and MDA-MB-231 cells. Scale bar = 200 μm. **** p<0.0001.
[0053] Figure 3 ZMF-24 inhibits the expression of key migration markers.
[0054] AD: Immunofluorescence assay to detect the effect of ZMF-24 on the expression of Snail and MMP-2 in BT-549 cells and MDA-MB-231 cells. Scale bar = 100 μm (Snail), scale bar = 5 μm (MMP-2). *** p<0.001; **** p<0.0001.
[0055] EG: Western blot was used to detect the effects of different concentrations of ZMF-24 on the expression of E-cadherin and MMP-2 in BT-549 cells and MDA-MB-231 cells. Image J software was used to analyze the relative expression of E-cadherin.
[0056] * p<0.05; ** p<0.01; **** p<0.0001.
[0057] Figure 4 ZMF-24 showed good anti-TNBC potential in vivo.
[0058] A, D: ZMF-24 inhibits the proliferation of TNBC xenograft tumors in nude mice. Changes in TNBC tumor volume during ZMF-24 treatment and representative images of tumors on the day of dissection.
[0059] B, C, E, F: The tumor volume and weight of each group were measured on the day of dissection.
[0060] p<0.05; ** p<0.01; **** p<0.0001.
[0061] G, H: Body weight changes of mice in each group treated with ZMF-24 and representative images of the heart, liver, spleen, lung, and kidney of mice on the day of dissection.
[0062] Figure 5 HE staining of the heart, liver, spleen, lung and kidney of mice in different groups. DETAILED DESCRIPTION
[0063] The specific implementation modes of the present invention are further described below in conjunction with embodiments, but the present invention is not limited to the scope of the embodiments.
[0064] Example 1 Compounds 1 to 24 were prepared by the following synthetic method:
[0065]
[0066] To a solution of dichloromethane (10.0 ml) containing a carboxylic acid derivative (1.0 mmol) and DCC (1.0 mmol), Miliusol (1.0 mmol) and an appropriate amount of DMAP catalyst were added after 15 minutes and then stirred for 8 hours. When the starting material was completely consumed, the reaction suspension was cooled to 0° C. for 2 hours, filtered, and washed with 15 ml of dichloromethane. The organic layer was washed with saturated sodium bicarbonate aqueous solution and brine, then dried over anhydrous sodium sulfate. After removing the solvent under reduced pressure, a crude product was obtained and purified by silica gel column chromatography with a yield of 49-95%.
[0067] Compound 1 1 H-NMR (600MHz, CDCl3), δ (ppm): 6.82 (1H, dd, J = 10.1, 3.9Hz), 6.1 (1H, d, J = 1 0.1Hz),5.66(1H,m),5.35(1H,d,J=9.9Hz),5.10(1H,d,J=9.9Hz),5.00(1H, m),4.99(1H,m),3.99(2H,m),3.32(1H,d,J=17.6Hz),2.4(1H,d,J=17.6Hz), 2.29(2H,m),2.03(4H,m),1.70(3H,s)1.68(3H,s),1.59(3H,s),1.47(9H,s); 13 C-NMR (150MHz, CDCl3), δ (ppm): 194.7, 174.3, 169.5, 155.7, 144.9, 143.4, 132.2, 131.0, 123.2, 118. 2,81.0,80.5,66.0,52.2,42.5,39.7,37.2,36.4,28.3,28.3,28.3,26.0,25.7,17.8,16.9.HRMS(ESI)+ Calculated for C 25 H 35 NO7, [M+H] + : m / z 462.2486, found 462.2398, HPLC(t R = 25.55 min, 96.3%).
[0068] Compound 2 1 1H-NMR (600 MHz, CDCl3), δ (ppm): 6.14 (2H, m), 6.09 (1H, dd, J = 10.1, 3.9 Hz), 5.86 (1H, d, J = 10.1 Hz), 5.63 (1H, m), 5.52 (1H, d, J = 10.0 Hz), 5.15 (1H, d, J = 10.0 Hz), 5.00 (1H, m), 4.00 (2H, m), 3.71 (2H, m), 3.39 (1H, d, J = 17.6 Hz), 2.45 (1H, d, J = 17.6 Hz), 2.29 (2H, m), 2.22 (4H, m), 1.69 (3H, s) 1.60 (3H, s), 1.58 (3H, s), 0.96 (3H, s); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 194.9, 174.5, 165.4, 154.1, 151.8, 147.9, 130.7, 122.6, 122.6, 120.1, 118.5, 80.9, 64.7, 52.3, 39.6, 34.5, 32.7, 30.8, 26.3, 24.6, 21.4, 17.7, 16.8, 13.7. HRMS(ESI) + Calculated for C 24 H 32 O5, [M+H] + : m / z 401.2323, found 401.2323, HPLC(t R = 27.06 min, 100.0%).
[0069] Compound 3 11H-NMR (600 MHz, CDCl3), δ (ppm): 6.82 (1H, dd, J = 10.2, 3.8 Hz), 6.18 (1H, d, J = 10.2 Hz), 6.07 (1H, m), 5.95 (1H, m), 5.61 (1H, m), 5.45 (1H, d, J = 9.9 Hz), 5.15 (1H, d, J = 9.9 Hz), 5.00 (1H, m), 3.32 (1H, m), 3.03 (1H, m), 2.94 (1H, m), 2.81 (2H, m), 2.73 (2H, m), 2.5 (2H, m), 2.41 (1H, m), 2.27 (1H, m) 2.24 (1H, m), 2.03 (5H, m), 1.85 (1H, m), 1.70 (3H, s), 1.69 (3H, s) 1.60 (3H, s), 1.45 (1H, m), 1.36 (1H, m), 1.26 (2H, m); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 194.7, 174.5, 172.0, 144.8, 144.3, 137.8, 136.2, 132.2, 131.9, 130.7, 123.2, 118.3, 81.1, 65.3, 52.3, 49.5, 44.2, 43.7, 42.4, 39.7, 38.8, 37.1, 36.4, 30.6, 30.1, 29.5, 26.0, 25.7, 17.7, 16.9. HRMS (ESI) + calculated for C 30 H 39 NO6, [M + H] + : m / z 510.2850, found 510.2858, HPLC (t R = 27.02 min, 96.8%). Compound 4 11H-NMR (600 MHz, CDCl3), δ (ppm): 7.51 (1H, m), 7.02 (1H, s), 6.95 (1H, m), 6.90 - 6.87 (2H, m), 6.82 (1H, m), 6.75 (1H, m), 6.09 (1H, m), 6.02 (2H, m), 5.97 (1H, m), 5.67 (1H, m), 5.54 (1H, d, J = 10.0 Hz), 5.17 (1H, d, J = 10.0 Hz), 5.01 (1H, m), 3.39 (1H, d, J = 17.5 Hz), 2.48 (1H, d, J = 17.5 Hz), 2.31 (2H, m), 2.04 (4H, m), 1.72 (2H, s) 1.69 (3H, s), 1.62 (3H, s), 1.60 (3H, m); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 194.9, 174.5, 165.9, 148.9, 148.4, 146.8, 144.5, 144.3, 141.8, 132.1, 130.7, 125.8, 123.9, 123.4, 123.2., 118.5, 118.4, 108.6, 105.9, 101.5, 80.9, 64.8, 52.3, 39.6, 37.0, 36.5, 26.0, 25.7, 17.8, 16.9. HRMS (ESI) + calculated for C 30 H 32 O7, [M + H] + : m / z 505.2221, found 505.2229, HPLC (t R = 29.85 min, 95.2%).
[0070] Compound 5 1 1H-NMR (600 MHz, CDCl3), δ (ppm): 8.23 (1H, s), 6.94 (1H, dd, J = 10.2, 3.8 Hz), 6.17 (1H, d, J = 10.2 Hz), 5.85 (1H, m), 5.65 (1H, d, J = 10.1 Hz), 5.17 (1H, d, J = 10.1 Hz), 5.01 (1H, m), 3.41 (1H, d, J = 17.5 Hz), 2.59 (1H, dd, J = 14.7, 4.1 Hz), 2.37 (1H, dd, J = 14.7, 4.1 Hz), 2.34 (1H, d, J = 17.5 Hz), 2.04 (4H, m), 1.78 (3H, s) 1.70 (3H, s), 1.60 (3H, s); 13C-NMR (150 MHz, CDCl3), δ (ppm): 194.6, 174.5, 159.2, 146.0, 145.4, 143.2, 137.2, 132.2, 132.2, 131.3, 123.3, 118.1, 80.9, 66.1, 52.4, 39.7, 37.0, 36.4, 26.0, 25.7, 17.7, 16.8. HRMS (ESI) + calculated for C 22 H 24 BrNO5S, [M + H] + : m / z 494.0631, found 494.0632, HPLC (t R =27.21 min, 95.0%).
[0071] Compound 6 1 1H-NMR (600 MHz, CDCl3), δ (ppm): 7.69 (1H, m), 7.43 (2H, m), 7.34 (1H, s), 7.20 (1H, m), 7.00 (1H, dd, J=10.1, 3.4 Hz), 6.16 (1H, d, J=10.1 Hz), 5.81 (1H, m), 5.62 (1H, d, J=9.9 Hz), 5.20 (1H, d, J=9.9 Hz), 5.02 (1H, m), 4.13 (3H, s), 3.42 (1H, d, J=17.5 Hz), 2.61 (1H, dd, J=14.7, 3.9 Hz), 2.40 (1H, dd, J=14.7, 3.9 Hz), 2.33 (1H, d, J=17.5 Hz), 2.04 (4H, m), 1.72 (3H, s) 1.70 (3H, s), 1.61 (3H, s); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 194.8, 174.5, 160.9, 144.8, 144.1, 140.1, 132.1, 130.9, 125.8, 125.7, 123.3, 122.8, 121.0, 118.4, 111.0, 110.3, 80.9, 65.2, 52.5, 39.7, 36.9, 36.5, 33.9, 31.7, 26.0, 25.7, 17.8, 17.0. HRMS (ESI) + calculated for C 28 H 31 NO5, [M + H] + : m / z462.2275, found 462.2268, HPLC (t R= 30.57 min, 98.3%).
[0072]
[0073] Compound 7 1 1H-NMR (600 MHz, CDCl3), δ (ppm): 7.26 (1H, m), 6.99 (1H, m), 6.97 (1H, m), 6.81 (1H, dd, J = 10.2, 3.8 Hz), 6.09 (1H, d, J = 10.2 Hz), 5.63 (1H, m), 5.40 (1H, d, J = 10.0 Hz), 5.12 (1H, d, J = 10.0 Hz), 5.00 (1H, m), 3.94 (2H, m), 3.36 (1H, d, J = 16.6 Hz), 2.42 (1H, d, J = 16.6 Hz), 2.23 (2H, m), 2.01 (4H, m), 1.69 (3H, s), 1.62 (3H, s) 1.59 (3H, s); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 194.6, 174.7, 169.4, 144.5, 143.3, 133.7, 132.1, 131.0, 127.3, 127.0, 125.6, 123.2, 118.4, 80.7, 65.7, 52.3, 39.6, 36.9, 36.3, 35.5, 26.0, 25.7, 17.7, 16.8. HRMS (ESI) + calculated for C 31 H 33 NO6S, [M + H] + : m / z 548.2101, found 548.2103, HPLC (t R = 18.74 min, 98.3%).
[0074] Compound 8 11H-NMR (600 MHz, CDCl3), δ (ppm): 8.12 (1H, m), 7.58 (1H, m), 7.51 (1H, m), 7.45 (1H, m), 6.75 (1H, dd, J = 10.1, 3.4 Hz), 6.0 (1H, d, J = 10.1 Hz), 5.70 (1H, m), 5.62 (1H, d, J = 10.3 Hz), 5.16 (1H, d, J = 10.3 Hz), 4.98 (1H, m), 3.28 (1H, d, J = 17.5 Hz), 2.37 (1H, m), 2.31 (1H, m), 2.28 (1H, d, J = 17.5 Hz), 2.04 (4H, m), 1.67 (3H, s) 1.59 (3H, s), 1.52 (3H, s); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 194.3, 174.1, 165.7, 145.9, 144.8, 133.2, 132.2, 131.4, 128.5, 124.5, 123.1, 120.5, 118.0, 108.7, 80.8, 67.3, 52.2, 48.9, 39.6, 36.9, 36.2, 33.7, 25.9, 25.7, 17.7, 16.8. HRMS (ESI) + calculated for C 26 H 29 N3O5, [M + H] + : m / z 464.2180, found 464.2185, HPLC (t R = 26.39 min, 95.1%).
[0075] Compound 9 1 1H-NMR (600 MHz, CDCl3), δ (ppm): 6.77 (3H, m), 6.72 (1H, dd, J = 10.1, 3.9 Hz), 6.0 (1H, d, J = 10.1 Hz), 5.97 (2H, m), 5.59 (1H, m), 5.36 (1H, d, J = 9.9 Hz), 5.10 (1H, d, J = 9.9 Hz), 4.9 (1H, m), 3.6 (2H, s), 3.36 (1H, d, J = 17.6 Hz), 2.38 (1H, d, J = 17.6 Hz), 2.26 (2H, m), 2.03 (4H, m), 1.69 (3H, s) 1.60 (3H, s), 1.58 (3H, s); 1313C-NMR (150 MHz, CDCl3), δ (ppm): 194.7, 174.5, 170.6, 148.1, 147.1, 144.3, 143.5, 132.2, 130.9, 126.4, 123.2, 122.4, 118.5, 109.4, 108.5, 101.2, 80.7, 65.3, 52.3, 40.9, 39.6, 36.7, 36.3, 26.0, 25.7, 17.8, 16.8. HRMS (ESI) + calculated for C 27 H 30 O7, [M + H] + : m / z 467.2064, found 467.2065, HPLC (t R = 27.01 min, 96.3%).
[0076] Compound 10 1 1H NMR (600 MHz, CDCl3), δ (ppm): 7.25 (2H, m), 7.25 (2H, m), 6.78 (1H, dd, J = 10.1, 3.9 Hz), 6.0 (1H, d, J = 10.1 Hz), 5.64 (1H, m), 5.35 (1H, d, J = 10.0 Hz), 5.10 (1H, d, J = 10.0 Hz), 5.0 (1H, m), 3.83 (2H, s), 3.37 (1H, d, J = 17.6 Hz), 2.39 (1H, d, J = 17.6 Hz), 2.27 (1H, m), 2.23 (1H, m), 2.03 (4H, m), 1.68 (3H, s) 1.59 (3H, s), 1.56 (3H, s); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 194.6, 174.5, 170.3, 163.1, 144.4, 143.4, 132.2, 130.9, 123.2, 118.5, 115.9, 115.7, 80.7, 65.5, 52.3, 40.5, 39.6, 36.8, 36.3, 31.4, 30.2, 25.9, 25.7, 17.7, 16.7. HRMS (ESI) + calculated for C 26 H 29 FO5, [M + H] + : m / z 441.2072, found 441.2076, HPLC (t R = 27.26 min, 95.0%).
[0077] Compound 11 1 H NMR(600MHz,CDCl3),δ(ppm):7.43(1H,m),7.25(2H,m),6.78(1H,dd,J=10.1,3.7Hz),6.0(1H,d,J=10.1Hz),5.64(1H,m),5.35(1H,d,J=10.0Hz),5.10(1H,d,J=10.0Hz),5.0(1H,m),3.83(2H,s),3.37(1H,d,J=17.6Hz),2.43(1H,m),2.28(1H,m),2.24(1H,d,J=17.6Hz),2.01(4H,m),1.68(3H,s)1.59(3H,s),1.56(3H,s); 13 C-NMR(150MHz,CDCl3),δ(ppm):194.6,174.5,169.1,144.3,143.2,143.1,135.2,134.5,132.2,132.1,130.1,129.6,127.6,123.2,118.5,80.6,65.7,52.3,39.6,38.8,36.7,36.2,25.7,17.8,16.7.HRMS(ESI) + calculated for C 26 H 28 Cl2O5,[M+H] + :m / z 491.1387,found491.1393,HPLC(t R =30.02min,96.8%).
[0078] Compound 12 1 H-NMR(600MHz,CDCl3),δ(ppm):7.30(1H,m),7.19(1H,m),7.01(1H,m),6.8(1H,dd,J=10.1,3.9Hz),6.0(1H,d,J=10.1Hz),5.64(1H,m),5.35(1H,d,J=10.0Hz),5.10(1H,d,J=10.0Hz),5.0(1H,m),3.83(2H,s),3.37(1H,d,J=17.6Hz),2.4(1H,d,J=17.6Hz),2.28(2H,m),2.03(4H,m),1.69(3H,s)1.6(3H,s),1.58(3H,s); 1313C-NMR (150 MHz, CDCl3), δ (ppm): 194.5, 174.5, 169.4, 162.8, 161.2, 144.4, 143.2, 135.2, 135.1, 132.2, 131.0, 123.2, 118.5, 117.3, 114.6, 80.7, 65.7, 52.3, 39.6, 38.7, 36.7, 36.2, 26.0, 25.7, 17.7, 16.8. HRMS (ESI) + calculated for C 26 H 28 ClFO5, [M + H] + : m / z 475.1682, found 475.1686, HPLC (t R = 28.63 min, 95.1%).
[0079] Compound 13 1 1H-NMR (600 MHz, CDCl3), δ (ppm): 7.65 (1H, s), 6.83 (1H, dd, J = 10.1, 3.9 Hz), 6.12 (1H, d, J = 10.1 Hz), 5.73 (1H, m), 5.31 (2H, m), 5.14 (1H, m), 5.08 (1H, m), 4.99 (1H, m), 3.61 (3H, s), 3.60 (2H, s), 3.38 (3H, s), 3.28 (1H, d, J = 17.4 Hz), 2.47 (1H, d, J = 17.4 Hz), 2.33 (1H, m), 2.28 (1H, m), 2.04 (4H, m), 1.68 (3H, s) 1.66 (3H, s), 1.59 (3H, s); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 196.3, 175.0, 155.4, 152.9, 151.5, 149.1, 148.4, 145.4, 143.0, 132.2, 129.0, 123.2, 118.4, 106.9, 82.0, 63.2, 52.3, 39.7, 39.4, 37.9, 32.2, 31.4, 30.6, 30.1, 29.9, 25.7, 25.3, 24.5, 17.7, 16.9. HRMS (ESI) + calculated for C 27 H 32 N4O7, [M + H] + : m / z 525.2344, found 525.2349, HPLC (t R=20.24min,97.5%).
[0080]
[0081] Compound 14 1 H-NMR (600MHz, CDCl3), δ (ppm): 7.64 (1H, s), 7.50 (2H, d, J = 8.4Hz), 7.21 (2H, d, J = 8.4 Hz),6.78(1H,dd,J=10.2,3.8Hz),6.05(1H,d,J=10.2Hz),5.58(1H,m),5.34(1H,d,J= 10.0Hz),5.09(1H,d,J=10.0Hz),4.99(1H,m),3.67(2H,s),3.34(1H,d,J=17.2Hz),2. 35(1H,d,J=17.2Hz),2.23(2H,m),2.16(3H,s),2.00(4H,m)1.67(3H,s),1.58(6H,s); 13 C-NMR (150MHz, CDCl3), δ (ppm): 196.3, 172.2, 168.5, 168.5, 136.9, 132.2, 129.8, 129.8, 128.9, 123.3, 120.1, 1 20.1,118.5,82.1,63.2,52.1,40.6,39.7,39.5,37.9,31.4,30.1,29.7,26.0,25.7,24.5,17.7,16.9.HRMS(ESI) + calculated for C 28 H 33 NO6,[M+H] + :m / z 480.2381,found 480.2385,HPLC(t R =8.48min,97.8%).
[0082] Compound 15 11H-NMR (600 MHz, CDCl3), δ (ppm): 7.34 (1H, d, J = 8.2 Hz), 7.18 (1H, d, J = 8.2 Hz), 7.17 (1H, dd, J = 10.1, 3.9 Hz), 6.5 (1H, s), 6.0 (1H, d, J = 10.1 Hz), 5.59 (1H, m), 5.38 (1H, d, J = 10.0 Hz), 5.11 (1H, d, J = 10.0 Hz), 4.9 (1H, m), 3.6 (2H, s), 3.35 (1H, d, J = 17.6 Hz), 2.38 (1H, d, J = 17.6 Hz), 2.26 (2H, m), 2.03 (4H, m), 1.69 (3H, s) 1.60 (3H, s), 1.58 (3H, s), 1.53 (9H, s); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 194.7, 174.5, 170.6, 152.7, 144.5, 143.7, 137.8, 132.1, 130.9, 130.9, 129.7, 129.7, 127.4, 123.2, 123.2, 118.9, 118.4, 80.8, 65.4, 52.3, 40.7, 39.6, 36.8, 36.3, 28.3, 28.3, 28.3, 26.0, 25.7, 17.8, 17.0. HRMS (ESI) + calculated for C 31 H 39 NO7, [M + H] + : m / z 538.2799, found 538.2803, HPLC (t R = 27.91 min, 98.9%).
[0083] Compound 16 1 1H-NMR (600 MHz, CDCl3), δ (ppm): 7.53 (2H, d, J = 8.5 Hz), 7.39 (1H, s), 7.23 (2H, d, J = 8.5 Hz), 6.77 (1H, dd, J = 10.2, 3.8 Hz), 6.06 (1H, d, J = 10.2 Hz), 5.59 (1H, m), 5.36 (1H, d, J = 10.0 Hz), 5.10 (1H, d, J = 10.0 Hz), 4.99 (1H, m), 3.68 (2H, s), 3.33 (1H, d, J = 17.6 Hz), 2.36 (1H, d, J = 17.6 Hz), 2.2 (2H, m), 2.01 (4H, m), 1.68 (3H, s), 1.59 (6H, s) 1.32 (9H, s); 1313C-NMR (150 MHz, CDCl3), δ (ppm): 194.6, 176.7, 174.5, 170.4, 144.5, 143.6, 137.5, 132.1, 130.8, 129.6, 129.6, 128.6, 123.2, 120.4, 120.4, 118.3, 80.7, 65.3, 52.2, 40.7, 39.6, 39.6, 36.7, 36.3, 27.5, 27.5, 27.5, 26.0, 25.6, 17.7, 16.8. HRMS (ESI) + calculated for C 31 H 39 NO6, [M + H] + : m / z 522.2850, found 522.2854, HPLC (t R = 26.33 min, 100.0%).
[0084] Compound 17 1 1H-NMR (600 MHz, CDCl3), δ (ppm): 8.36 (1H, s), 7.59 (1H, d, J = 8.2 Hz), 7.50 (1H, d, J = 8.2 Hz), 7.21 (2H, m), 6.76 (1H, dd, J = 10.2, 3.8 Hz), 6.04 (1H, d, J = 10.2 Hz), 5.58 (1H, m), 5.34 (1H, m), 5.09 (1H, m), 4.97 (1H, m), 3.72 (1H, t, J = 4.2 Hz), 3.66 (1H, d, J = 3.6 Hz), 3.47 (2H, s), 3.31 (1H, m), 2.34 (1H, m), 2.26 (1H, m), 2.21 (1H, m), 2.01 (4H, m), 1.69 (3H, s), 1.63 (6H, m); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 196.3, 172.1, 169.9, 137.1, 129.8, 129.8, 123.3, 120.1, 120.1, 118.5, 82.0, 68.6, 63.2, 58.9, 52.0, 40.6, 39.7, 127.0, 123.2, 123.1, 120.0, 118.3, 65.4, 65.4, 52.2, 39.5, 36.3, 25.9, 25.6. HRMS (ESI) + calculated for C 29 H 33 NO6, [M + H] +: m / z 492.2381, found 492.2386, HPLC(t R = 9.71 min, 99.4%).
[0085] Compound 18 1 H-NMR(600 MHz, CDCl3), δ(ppm): 7.64(1H, s), 7.51(2H, d, J = 7.6 Hz), 7.21(2H, d, J = 7.6 Hz), 6.77(1H, dd, J = 10.2, 3.8 Hz), 6.06(1H, d, J = 10.2 Hz), 5.59(1H, m), 5.36(1H, d, J = 10.0 Hz), 5.09(1H, d, J = 10.0 Hz), 4.49(1H, m), 3.67(2H, s), 3.35(1H, d, J = 17.64 Hz), 2.36(1H, d, J = 17.6 Hz), 2.23(2H, m), 2.01(4H, m), 1.68(3H, s), 1.59(3H, s)1.57(3H, s), 1.52(1H, s), 1.08(2H, m), 0.85(2H, m); 13 C-NMR(150 MHz, CDCl3), δ(ppm): 194.6, 174.7, 171.9, 170.5, 144.5, 143.6, 137.6, 132.1, 130.8, 129.6, 129.6, 123.2, 123.2, 120.0, 118.3, 80.7, 65.3, 52.2, 40.7, 39.6, 36.7, 36.3, 33.9, 26.0, 25.7, 17.7, 16.8, 15.7, 8.03, 8.03. HRMS(ESI) + calculated for C 30 H 35 NO6, [M + H] + : m / z 506.2537, found 506.2542, HPLC(t R = 25.91 min, 100.0%).
[0086] Compound 19 11H-NMR (600 MHz, CDCl3), δ (ppm): 8.07 (1H, s), 7.67 (1H, m), 7.62 (2H, d, J = 8.5 Hz), 7.55 (1H, m), 7.25 (1H, d, J = 8.5 Hz), 7.12 (1H, m), 6.77 (1H, dd, J = 10.2, 3.8 Hz), 6.06 (1H, d, J = 10.2 Hz), 5.59 (1H, m), 5.35 (1H, d, J = 10.02 Hz), 5.08 (1H, d, J = 10.02 Hz), 4.97 (1H, m) 3.69 (2H, s), 3.34 (1H, d, J = 17.2 Hz), 2.35 (1H, d, J = 17.2 Hz), 2.23 (2H, m), 2.00 (4H, m) 1.76 (3H, s), 1.67 (3H, s), 1.58 (3H, s); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 194.6, 174.7, 170.4, 160.0, 144.6, 143.5, 139.2, 137.2, 132.1, 130.9, 130.8, 129.7, 129.7, 128.9, 128.5, 127.8, 123.1, 120.7, 120.7, 118.3, 80.8, 65.4, 52.2, 40.7, 39.6, 36.7, 36.2, 30.9, 26.2, 25.9, 25.7, 17.7, 16.8. HRMS (ESI) + calculated for C 31 H 33 NO6S, [M + H] + : m / z 548.2101, found 548.2105, HPLC (t R = 24.86 min, 98.9%).
[0087] Compound 20 11H-NMR (600 MHz, CDCl3), δ (ppm): 7.96 (1H, s), 7.88 (2H, d, J = 7.8 Hz), 7.66 (2H, d, J = 7.8 Hz), 7.57 (1H, m), 7.51 (2H, m), 7.27 (2H, m), 6.77 (1H, dd, J = 10.2, 3.8 Hz), 6.06 (1H, d, J = 10.2 Hz), 5.61 (1H, m), 5.37 (1H, d, J = 10.0 Hz), 5.10 (1H, d, J = 10.0 Hz), 4.99 (1H, m), 3.72 (2H, s), 3.35 (1H, d, J = 17.64 Hz), 2.37 (1H, d, J = 17.64 Hz), 2.24 (2H, m), 2.01 (4H, m), 1.68 (3H, s), 1.59 (3H, s) 1.57 (3H, s); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 194.6, 174.7, 170.4, 165.7, 144.5, 143.5, 143.4, 137.5, 134.8, 132.1, 132.0, 130.9, 129.8, 129.8, 129.0, 128.8, 128.8, 127.0, 123.1, 123.1, 120.6, 118.4, 80.7, 65.4, 52.3, 40.8, 39.6, 36.7, 36.3, 26.0, 25.7, 17.7, 16.8. HRMS (ESI) + calculated for C 33 H 35 NO6, [M + H] + : m / z 542.2537, found 542.2540, HPLC (t R = 26.36 min, 97.6%).
[0088] Compound 21 11H-NMR (600 MHz, CDCl3), δ (ppm): 9.82 (1H, s), 8.28 (1H, d, J = 7.7 Hz), 7.68 (2H, d, J = 7.9 Hz), 7.51 (1H, m), 7.27 (2H, d, J = 7.9 Hz), 7.14 (1H, m), 7.05 (1H, d, J = 7.7 Hz), 6.77 (1H, dd, J = 10.2, 3.8 Hz), 6.06 (1H, d, J = 10.2 Hz), 5.59 (1H, m), 5.38 (1H, d, J = 9.0 Hz), 5.11 (1H, d, J = 9.0 Hz), 4.99 (1H, m), 4.07 (3H, s), 3.70 (2H, s), 3.33 (1H, d, J = 17.6 Hz), 2.38 (1H, dd, J = 14.6, 3.6 Hz), 2.24 (2H, d, J = 17.6 Hz), 2.00 (4H, m), 1.66 (3H, s), 1.59 (3H, s), 1.57 (3H, s); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 196.5, 175.4, 171.4, 164.1, 158.1, 145.4, 144.5, 138.7, 134.2, 133.4, 132.9, 131.7, 130.5, 130.5, 129.4, 124.1, 122.6, 122.4, 121.6, 121.6, 119.2, 112.4, 87.7, 66.3, 57.1, 53.1, 41.7, 40.4, 37.7, 37.2, 26.8, 26.5, 18.6, 17.7. HRMS (ESI) + calculated for C 34 H 37 NO7, [M + H] + : m / z 572.2643, found 572.2646, HPLC (t R = 27.10 min, 100.0%).
[0089] Compound 22 11H-NMR (600 MHz, CDCl3), δ (ppm): 7.65 (2H, d J = 8.5 Hz), 7.57 (1H, s), 7.32 (1H, m), 7.25 (2H, d J = 8.5 Hz), 6.79 (1H, dd, J = 10.2, 3.8 Hz), 6.60 (2H, m), 6.06 (1H, d, J = 10.2 Hz), 5.59 (1H, m), 5.38 (1H, d, J = 9.9 Hz), 5.12 (1H, d, J = 9.9 Hz), 4.99 (1H, m), 3.83 (6H, s), 3.69 (2H, s), 3.30 (1H, d, J = 17.6 Hz), 2.38 (1H, d, J = 17.6 Hz), 2.27 - 2.22 (2H, m), 2.05 (4H, m), 1.68 (3H, s), 1.61 (3H, s), 1.59 (3H, s); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 194.7, 174.5, 170.5, 163.8, 157.5, 144.6, 137.8, 132.1, 131.2, 130.8, 129.6, 129.6, 129.5, 128.5, 123.2., 120.0, 120.0, 119.8, 118.3 115.6, 104.1, 80.8, 65.4, 56.0, 52.3, 40.7, 39.6, 36.9, 36.3, 32.7, 30.8, 25.9, 25.7, 17.7, 16.8. HRMS (ESI) + calculated for C 35 H 39 NO8, [M + H] + : m / z 602.2748, found 602.2753, HPLC (t R = 24.21 min, 98.0%).
[0090] Compound 23 11H-NMR (600 MHz, CDCl3), δ (ppm): 7.98 (1H, s), 7.76 (1H, d, J = 3.8 Hz), 7.66 (2H, d, J = 8.3 Hz), 7.47 (1H, d, J = 3.8 Hz), 7.43 (1H, m), 7.39 (1H, m), 7.30 (2H, d, J = 8.3 Hz), 6.77 (1H, dd, J = 10.2, 3.8 Hz), 6.06 (1H, d, J = 10.2 Hz), 5.60 (1H, m), 5.37 (1H, d, J = 9.9 Hz), 5.11 (1H, d, J = 9.9 Hz), 4.99 (1H, m), 3.71 (2H, s), 3.34 (1H, d, J = 17.6 Hz), 2.38 (1H, d, J = 17.6 Hz), 2.24 (2H, m), 2.00 (4H, m), 1.69 (3H, s), 1.64 (3H, s), 1.59 (3H, s); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 195.5, 175.4, 171.3, 165.3, 145.4, 144.4, 137.9, 135.9, 133.0, 132.7, 131.8, 131.4, 131.3, 130.7, 130.7, 130.2, 128.3 124.0, 121.3, 121.3, 119.2, 81.6, 66.3, 53.2, 41.6, 40.5, 40.5, 37.6, 37.2, 26.8, 26.5, 18.6, 17.7. HRMS (ESI) + calculated for C 33 H 34 ClNO6, [M + H] + : m / z 576.2147, found 576.2152, HPLC (t R = 25.96 min, 98.9%).
[0091] Compound 24 11H-NMR (600 MHz, CDCl3), δ (ppm): 7.85 (1H, s), 7.75 (1H, m), 7.64 (2H, m), 7.53 (2H, m), 7.38 (3H, m), 7.24 (2H, m), 6.77 (1H, dd, J = 10.2, 3.8 Hz), 6.58 (1H, m), 6.06 (2H, d, J = 10.2 Hz), 5.59 (1H, m), 5.35 (2H, d, J = 10.0 Hz), 5.09 (1H, d, J = 10.0 Hz), 4.98 (1H, m), 3.69 (2H, s), 3.36 (1H, d, J = 17.6 Hz), 2.30 (1H, d, J = 17.6 Hz), 2.23 (2H, m), 2.00 (4H, m) 1.75 (3H, s), 1.67 (3H, s), 1.58 (3H, s); 13 13C-NMR (150 MHz, CDCl3), δ (ppm): 194.6, 174.7, 170.4, 144.6, 143.5, 142.4, 134.5, 132.1, 130.9, 130.0, 129.7, 128.9, 128.9, 127.9, 127.9, 123.2, 120.3, 118.3, 80.8, 65.3, 52.3, 40.8, 39.6, 36.7, 36.3, 32.7, 30.9, 26.2, 26.0, 25.7, 25.4, 25.3, 24.7, 17.7, 16.8. HRMS (ESI) + calculated for C 35 H 37 NO6, [M + H] + : m / z 568.2694, found 568.2698, HPLC (t R = 27.85 min, 97.2%). Compound 25 1H-NMR (600MHz, CDCl3), δ (ppm): 8.52 (1H, m), 7.59 (2H, m), 7.51 (1H, d, J = 7.8Hz), 7.46 (1H, d ,J=7.8Hz),7.43-7.35(3H,m),7.25(2H,m),6.77(1H,dd,J=10.2,3.8Hz),6.06(1H,d,J=10. 2Hz),5.59(1H,m),5.51(1H,s),5.36(1H,m),5.11(1H,m),4.99(1H,m),3.69(2H,m),3.35(1 H,d,J=17.1Hz),2.38(1H,d,J=17.1Hz),2.24(2H,m),2.00(4H,m),1.69(3H,s),1.63(6H,m); 13 C-NMR (150MHz, CDCl3), δ (ppm): 194.6, 174.5, 170.4, 170.3, 168.5, 165.3, 144.5, 144.5, 143.5, 143.4, 136.7, 136.4, 136.3, 132.1, 130.9 ,130.8,129.8,129.7,129.3,129.0,128.6,127.7,127.0,123.2,123.1,120.0,118.3,65.4,65.4,52.2,39.5,36.3,25.9,25.6.HRMS(ESI) + calculated for C 34 H 36 ClNO6,[M+H] + :m / z 590.2304,found590.2310,HPLC(t R =24.91min,97.4%).
[0092] Test Example 1 Evaluation of Antitumor Proliferation Activity of Compounds 1 to 25
[0093] Triple negative breast cancer TNBC cells were cultured at 6×10 3 The cells were seeded in a 96-well plate at a density of 100 μM and cultured according to standard conditions. After 24 hours and 48 hours of DMSO and each compound (100 μM, 50 μM, 25 μM, 12.5 μM, 6.25 μM, 3.125 μM, 1.5625 μM, 0.78125 μM), 20 μL of MTT solution was added to each well and incubated for 4 hours. The solution was then poured out, DMSO was added and mixed evenly, and the absorbance at 490 nm was measured with an enzyme marker. The results are as follows:
[0094] Table 1. Evaluation of anti-tumor proliferation activity of compounds 1 to 25
[0095]
[0096]
[0097] a Each compound was tested three times, and the data were expressed as mean ± SD.
[0098] The experimental results showed that most of the compounds showed potent anti-tumor proliferation activity, among which compound 24 exhibited the strongest anti-proliferative activity.
[0099] Table 2. Selectivity of compound 24 for normal cells and tumor cells.
[0100]
[0101] The above results indicate that compound 24 exhibits a selectivity of about 60 times higher for tumor cells than for normal cells, while the control drug paclitaxel exhibits no selectivity.
[0102] Test Example 2 Compound 24 (ZMF-24) inhibits tumor cell proliferation
[0103] To further investigate the effect of compound 24 on tumor cell proliferation, we first performed a clone formation assay. Compound 24 had a potent dose-dependent inhibitory effect on the proliferation of BT-549 and MDA-MB-231 cells ( Figure 1 AD). Subsequent 3D tumor sphere formation experiments also demonstrated that compound 24 could significantly inhibit the proliferation of TNBC cells ( Figure 1 E, F). Next, we used EdU proliferation assay to detect DNA replication of TNBC cells after treatment with compound 24. The results showed that compound 24 reduced the EdU fluorescence intensity of TNBC cells in a concentration-dependent manner, indicating that compound 24 significantly reduced the proliferation rate of TNBC cells ( Figure 1 G, I). In addition, we used immunofluorescence to measure the expression intensity of Ki-67 in TNBC cells to evaluate the effect of compound 24 on TNBC cell proliferation. The results showed that compound 24 significantly reduced the expression of Ki-67 ( Figure 1 H, J), further confirming that compound 24 has a strong anti-TNBC proliferation ability.
[0104] Experimental Example 3 Compound 24 (ZMF-24) has a strong anti-tumor cell migration ability
[0105] Next, we continued to study the effect of compound 24 on the migration ability of BT-549 cells and MDA-MB-231 cells. First, we performed a wound healing experiment. Figure 2 As shown in A and 2B, the BT-549 cells and MDA-MB-231 cells in the control group gradually healed over time. As the concentration of compound 24 increased, the healing ability of BT-549 cells and MDA-MB-231 cells decreased significantly, indicating that compound 24 had a significant inhibitory effect on the migration of TNBC cells. Subsequent Transwell experiments further confirmed the inhibitory effect of compound 24 on the migration ability of BT-549 and MDA-MB-231 cells (as shown in Figure 2A). Figure 2 C and D). Subsequently, some key molecular markers related to migration were detected. First, immunofluorescence technology was used to evaluate the expression and distribution of Snail, a recognized pro-migratory protein. The results showed that the expression of Snail in the BT-549 cell and MDA-MB-231 cell control groups was relatively high and mainly distributed in the cell nucleus. Treatment with compound 24 significantly reduced the expression of Snail in TNBC cells, especially the distribution of Snail in the cell nucleus ( Figure 3 A, B), which indicates that compound 24 inhibited Snail expression in TNBC. In addition, immunofluorescence was used to evaluate the expression of MMP-2. MMP-2 is a protein that promotes cancer development and can break down the extracellular matrix to enhance the migration potential of cancer cells. The expression of MMP-2 was abundant in BT-549 cells and MDA-MB-231 cells, indicating that TNBC has a strong migration potential. After treatment with compound 24, the expression of MMP-2 in TNBC cells was significantly reduced, proving that compound 24 inhibited the expression of MMP-2, further indicating that compound 24 has a strong anti-migratory ability ( Figure 3 C, D). Next, we used Western blot to detect the expression of MMP-2 and anti-migratory protein E-cadherin in TNBC cells. Compound 24 concentration-dependently led to increased E-cadherin content and decreased MMP-2 levels in TNBC cells, confirming the inhibitory effect of compound 24 on TNBC cell migration ( Figure 3 EG). In summary, compound 24 can strongly inhibit the migration of TNBC cells.
[0106] Test Example 4 In vivo antiproliferative activity of compound 24 (ZMF-24)
[0107] We further explored the therapeutic potential of compound 24 in a nude mouse TNBC cell xenograft tumor model. The experimental results showed that 5mg / kg, 10mg / kg and 20mg / kg of compound 24 could significantly reduce the proliferation rate of TNBC tumors, with 20mg / kg having the most significant effect ( Figure 4 A, D). In addition, by weighing the samples after the experiment, it was found that compound 24 could dose-dependently reduce tumor volume and weight ( Figure 4 B, C, E, F), indicating that compound 24 has good anti-proliferative potential in vivo. In addition, by monitoring the body weight of mice during compound 24 treatment, it was found that compound 24 had little effect on the body weight of mice, and the appearance of important organs (heart, liver, spleen, lung and kidney) taken after treatment did not change significantly, suggesting that compound 24 may not have obvious toxic side effects ( Figure 4 G, H). Subsequently, HE staining was used to detect changes in key organs of each group of mice, and no significant pathological changes were found in the organs of each group ( Figure 5 ).
Claims
1. A compound represented by formula I or a pharmaceutically acceptable salt thereof: in, R is -CO(CH2) n NHCOOR1, -CO(CH2) m R2, -CO(CH2) p CONHR3, -CO(CH2) n NHCOR4; R1 is C1-C6 alkyl, C1-C6 alkoxy; R2 is C2-C8 alkenyl, substituted or unsubstituted 5-10 membered aryl or heteroaryl, the heteroaryl contains 1-3 heteroatoms of N, O or S, and the substituent is halogen, C1-C6 alkyl, C1-C6 alkoxy, -NHCOR5, -NHCOOR6; R5 is C1-C6 alkyl, C1-C6 alkoxy, C2-C8 alkenyl, C3-C6 cycloalkyl, substituted or unsubstituted 5-6 membered aryl or heteroaryl, the heteroaryl contains 1-3 heteroatoms of N, O or S, and the substituent is halogen, C1-C6 alkyl, C1-C6 alkoxy; R6 is C1-C6 alkyl, C1-C6 alkoxy; R3 is (CH2) q R8; R8 is R4 is a substituted or unsubstituted C2-C8 alkenyl group, wherein the substituent is a 5-10 membered aryl or heteroaryl group, wherein the heteroaryl group contains 1-3 heteroatoms of N, O or S; n is 0-4; m is 0-4; p is 0-4; q is 0-4.
2. The compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof: in, R2 is C2-C8 alkenyl, substituted or unsubstituted Phenyl, wherein the substituent is F, Cl, Br, C1-C4 alkyl, C1-C4 alkoxy, -NHCOR5, -NHCOOR6; R5 is C1-C4 alkyl, C1-C4 alkoxy, C2-C4 alkenyl, C3-C6 cycloalkyl, substituted or unsubstituted Phenyl, halogen-substituted C1-C4 alkylphenyl, the substituent is C1-C4 alkyl, C1-C4 alkoxy; R6 is C1-C6 alkyl, C1-C6 alkoxy.
3. The compound of formula I according to claim 1 or 2 or a pharmaceutically acceptable salt thereof: in, R4 is a substituted or unsubstituted C2-C8 alkenyl group, wherein the substituent is 4. The compound of formula I according to claim 1, 2 or 3 or a pharmaceutically acceptable salt thereof: in, n is 1-2; m is 0-2; p is 1-2; q is 1-2.
5. A compound having the following structure or a pharmaceutically acceptable salt thereof:
6. The method for preparing the compound or a pharmaceutically acceptable salt thereof according to claim 5, characterized in that:
7. A pharmaceutical composition comprising the compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising the compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof and other anti-tumor drugs.
9. Use of the compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 7 or 8 in the preparation of an anti-tumor drug.
10. The use according to claim 9, characterized in that: The tumor is breast cancer.
